Neuroendocrine tumour (NET)
Open
Phase 2
This study is looking at standard chemotherapy and pembrolizumab followed by lenvatinib and pembrolizumab.
It is for people with a type of neuroendocrine cancer called and they:
are well enough to have treatment that reaches the whole body (systemic treatment)
haven’t started treatment yet
Recruitment start: 8 July 2024
Recruitment end: 31 July 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr David Pinato
Imperial College Healthcare NHS Trust
Merck, Sharp & Dohme LLC
Last reviewed: 26 May 2025
CRUK internal database number: 19803
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
